Cardiovascular disease-specific mortality after partial versus radical nephrectomy for stage II renal cancer: A SEER-based propensity-matched analysis
- 1Department of Urology, Jingzhou First People’s Hospital, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, 434000, China
- 2Center of Laboratory Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China
- 3The First Clinical Medical College, Ningxia Medical University, Yinchuan, Ningxia, 750004, China
Abstract
Background: Surgery remains standard treatment for localized renal cancer. Whether partial nephrectomy (PN), compared with radical nephrectomy (RN), affects long-term cardiovascular disease-specific mortality (CVD-SM) in stage II disease is uncertain. We assessed this association using competing-risk methods.
Methods: Patients with T2N0M0 renal cancer diagnosed in the SEER database from 2004 to 2022 were included. Missing tumor grade and unspecified T2 subclassification were addressed by multiple imputation. Propensity-score matching was performed within 10 imputed datasets. Cumulative incidence functions were estimated using the Aalen–Johansen method. Fine–Gray models were primary, with cause-specific Cox models as supportive analyses; estimates were pooled across imputations.
Results: The cohort included 14,602 patients (PN, n = 1294; RN, n = 13,308), with a median follow-up of 85 months. After matching, 1290–1292 patients per group were retained. Five-year CVD-SM cumulative incidence was 2.68% after PN and 3.07% after RN; 10-year estimates were 7.18% and 6.63%, respectively. No significant association was observed (Fine–Gray sHR, 1.10; 95% CI, 0.69–1.74; P = 0.690; Cox HR, 1.04; 95% CI, 0.66–1.64; P = 0.867). PN was associated with lower cancer-specific mortality (Fine–Gray sHR, 0.58; 95% CI, 0.42–0.80; P < 0.001).
Conclusion: Among patients with stage II renal cancer, surgical approach was not significantly associated with CVD-SM. However, estimate imprecision and unavailable cardiovascular and renal risk factors preclude claims of equivalence or exclusion of clinically meaningful effects. The potential cardiovascular benefit of PN remains uncertain. Its lower cancer-specific mortality should be interpreted cautiously because residual surgical-selection confounding may persist.
Synopsis: Cardiovascular disease-specific mortality represents an important long-term competing risk in patients with stage II renal cancer. No statistically significant association between surgical approach and cardiovascular disease-specific mortality was detected, leaving the cardiovascular survival advantage of partial nephrectomy uncertain.
Related
- Machine learning based predictive model for cardiovascular disease mortality risk in patients with stage 4 cardiovascular–kidney–metabolic syndrome
- Development and validation of a novel metabolic-inflammatory health-related nomogram for predicting in-hospital mortality in older patients with type 2 diabetes mellitus combined with cardiovascular disease
- The impact of histological subtype on positive surgical margins in patients with renal cell carcinoma undergoing robot-assisted partial nephrectomy: a multicenter retrospective cohort study using propensity score matching (the MSUG 94 group)
- Impact of Education in Disease Management Program for Patients with Diabetes Mellitus on All-Cause Mortality: A Propensity Score-Matched Cohort Study
- Cohort-specific childhood adversity measures and incident cardiovascular disease across four ageing cohorts: analyses of childhood hunger, later-life psychosocial indicators, and life-course burden
BibTeX
@article{hao2026cardiovascular,
title = {{Cardiovascular disease-specific mortality after partial versus radical nephrectomy for stage II renal cancer: A SEER-based propensity-matched analysis}},
author = {Yao Hao and Zhicheng Dai and Feng Li and Zhenxing Hu},
journal = {Translational Oncology},
year = {2026},
month = oct,
doi = {10.1016/j.tranon.2026.103083},
url = {https://doi.org/10.1016/j.tranon.2026.103083},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Cardiovascular disease-specific mortality after partial versus radical nephrectomy for stage II renal cancer: A SEER-based propensity-matched analysis
AU - Yao Hao
AU - Zhicheng Dai
AU - Feng Li
AU - Zhenxing Hu
PY - 2026
DA - 2026/10/21
JO - Translational Oncology
DO - 10.1016/j.tranon.2026.103083
UR - https://doi.org/10.1016/j.tranon.2026.103083
AB - Background: Surgery remains standard treatment for localized renal cancer. Whether partial nephrectomy (PN), compared with radical nephrectomy (RN), affects long-term cardiovascular disease-specific mortality (CVD-SM) in stage II disease is uncertain. We assessed this association using competing-risk methods. Methods: Patients with T2N0M0 renal cancer diagnosed in the SEER database from 2004 to 2022 were included. Missing tumor grade and unspecified T2 subclassification were addressed by multiple imputation. Propensity-score matching was performed within 10 imputed datasets. Cumulative incidence functions were estimated using the Aalen–Johansen method. Fine–Gray models were primary, with cause-specific Cox models as supportive analyses; estimates were pooled across imputations. Results: The cohort included 14,602 patients (PN, n = 1294; RN, n = 13,308), with a median follow-up of 85 months. After matching, 1290–1292 patients per group were retained. Five-year CVD-SM cumulative incidence was 2.68% after PN and 3.07% after RN; 10-year estimates were 7.18% and 6.63%, respectively. No significant association was observed (Fine–Gray sHR, 1.10; 95% CI, 0.69–1.74; P = 0.690; Cox HR, 1.04; 95% CI, 0.66–1.64; P = 0.867). PN was associated with lower cancer-specific mortality (Fine–Gray sHR, 0.58; 95% CI, 0.42–0.80; P < 0.001). Conclusion: Among patients with stage II renal cancer, surgical approach was not significantly associated with CVD-SM. However, estimate imprecision and unavailable cardiovascular and renal risk factors preclude claims of equivalence or exclusion of clinically meaningful effects. The potential cardiovascular benefit of PN remains uncertain. Its lower cancer-specific mortality should be interpreted cautiously because residual surgical-selection confounding may persist. Synopsis: Cardiovascular disease-specific mortality represents an important long-term competing risk in patients with stage II renal cancer. No statistically significant association between surgical approach and cardiovascular disease-specific mortality was detected, leaving the cardiovascular survival advantage of partial nephrectomy uncertain.
SN - 1936-5233
ER -